KBP-7018 hydrochloride

CAS No. 1613437-67-4

KBP-7018 hydrochloride( KBP 7018 hydrochloride | KBP7018 hydrochloride )

Catalog No. M12342 CAS No. 1613437-67-4

A novel potent, multikinase inhibitor with IC50 of 10, 7.6 and 25 nM for c-Kit, RET and PDGFRβ, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 963 Get Quote
50MG 1962 Get Quote
100MG 2520 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    KBP-7018 hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    A novel potent, multikinase inhibitor with IC50 of 10, 7.6 and 25 nM for c-Kit, RET and PDGFRβ, respectively.
  • Description
    A novel potent, multikinase inhibitor with IC50 of 10, 7.6 and 25 nM for c-Kit, RET and PDGFRβ, respectively; also potently inhibits FLT3, VEGFR2, Fyn, PDGFRα and VEGFR2; shows promising outcomes for the treatments of idiopathic pulmonary fibrosis (IPF).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    KBP 7018 hydrochloride | KBP7018 hydrochloride
  • Pathway
    Angiogenesis
  • Target
    c-Kit
  • Recptor
    c-Kit
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1613437-67-4
  • Formula Weight
    575.06
  • Molecular Formula
    C31H31ClN4O5
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    COC(=O)C1=CC2=C(C=C1)C(=C(N2)O)C(=NC3=CC4=C(C=C3)N(CC4)C(=O)CN5CCOCC5)C6=CC=CC=C6.Cl
  • Chemical Name
    Methyl (Z)-3-(((1-(2-morpholinoacetyl)indolin-5-yl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate hydrochloride

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Huang Z, et al. ACS Med Chem Lett. 2017 Sep 30;8(11):1142-1147. 2. Huang Z, et al. Drug Des Devel Ther. 2015 Aug 5;9:4319-28.
molnova catalog
related products
  • Cistanoside A

    Cistanoside A possesses protective activities on CCl4 induced hepatotoxicity in mice, which is involved with increasing free radicals clearing activities.

  • Bezuclastinib

    Bezuclastinib (CGT9486) is a novel, potent and highly selective tyrosine kinase and c-kit D816V inhibitor for the study of advanced mastocytosis.

  • Famitinib

    Famitinib (SHR1020) is a structural analogue of sunitinib, novel and potent multi-targeted RTK inhibitor.